Il22 immunoconjugates
AssigneePhilogen S.P.A.
InventorsFranziska Sophie Bootz, Dario Neri
Life of this patent
Estimating the term…
Abstract
The application relates to a conjugate comprising interleukin-22 (IL22) and an antibody molecule. The antibody molecule preferably binds an antigen associated with angiogenesis, such as the ED-A isoform of fibronectin. In particular, the application relates to the therapeutic use of such conjugates in the treatment of a disease/disorder, such as autoimmune diseases, including inflammatory bowel disease (IBD).
Claims20
A method of treating an autoimmune disease in a patient, the method comprising administering a therapeutically effective amount of a conjugate to the patient, the conjugate comprising interleukin-22 (IL22) and an antibody molecule, wherein the antibody molecule comprises an antigen-binding site which binds the Extra Domain-A (ED-A) of fibronectin and comprises the complementarity determining regions (CDRs) of antibody F8 set forth in SEQ ID NOs 1-6, and wherein the IL22 comprises the sequence set forth in SEQ ID NO:
- 11.
A method of delivering IL22 to sites of autoimmune disease in a patient comprising administering a conjugate to the patient, the conjugate comprising IL22 and an antibody molecule, wherein the antibody molecule comprises an antigen-binding site which binds the ED-A of fibronectin and comprises the CDRs of antibody F8 set forth in SEQ ID NOs 1-6, and wherein the IL22 comprises the sequence set forth in SEQ ID NO:
- 11.
A method of treating inflammation in a patient, the method comprising administering a therapeutically effective amount of a conjugate comprising IL22 and an antibody molecule to the patient, wherein the antibody molecule comprises an antigen-binding site which binds the ED-A of fibronectin and comprises the CDRs of antibody F8 set forth in SEQ ID NOs 1-6, and wherein the IL22 comprises the sequence set forth in SEQ ID NO:
- 11.
A method of delivering IL22 to sites of inflammation in a patient comprising administering a conjugate comprising IL22 and an antibody molecule to the patient, wherein the antibody molecule comprises an antigen-binding site which binds the ED-A of fibronectin and comprises the CDRs of antibody F8 set forth in SEQ ID NOs 1-6, and wherein the IL22 comprises the sequence set forth in SEQ ID NO:
- 11.
Dependencies are inferred from the claim text.